Drug Trial Radar · NCT07278479
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
138
Planned (sponsor's estimate)
Start
May 18, 2026
Primary completion
Sep 2028
Study completion Sep 2032
Sponsor
- Lead sponsor
- Molecular Partners AGIndustry
- Sponsor type
- Industry
- Collaborators
- Orano Med LLC
- First posted
- Dec 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[212Pb\]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.
Conditions
- Large Cell Neuroendocrine Carcinoma
- Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)
- Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
- Small Cell Lung Cancer (SCLC)
- Gastroenteropancreatic NEC (GEP NEC)
- NEC of the Bladder
- Other DLL3 Expressing epNEC
Interventions
[212Pb]Pb-MP0712Drug
Radioligand Therapy
[203Pb]Pb-MP0712Other
Radioligand Imaging Agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess incidence and severity of safety events following administration of [212Pb]Pb-DOTAM-MAM279Time frame: until 5 years after last dose
- To assess dose modifications of [212Pb]Pb-DOTAM-MAM279Time frame: until 5 years after last dose
- To estimate the maximum tolerated dose (MTD) and/or to define the recommended phase 2 dose (RP2D) for SCLC/LCNEC of the lung and epNECsTime frame: Phase 1, from start of treatment to end of first cycle (day 1 - 28)
- To evaluate the preliminary anti-tumor activity of [212Pb]Pb-DOTAM-MAM279 in the dose expansion partTime frame: Phase 2a only; 12 months
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
University of Miami
Miami, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Emory University Hospital
Atlanta, Georgia · Recruiting
University of Chicago
Chicago, Illinois · Recruiting
United Theranostics
Glen Burnie, Maryland · Recruiting
Nebraska Cancer Specialists
Omaha, Nebraska · Recruiting
United Theranostics
Princeton, New Jersey · Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.